WARREN, N.J.--(BUSINESS WIRE)--Oct 12, 2023--
Tevogen Bio Inc. (“Tevogen Bio”) congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio’s Innovation and Public Health Advisory Board, on being elected to serve as the President of the Global Virus Network. The Global Virus Network is a coalition comprised of leading virologists around the world, committed to solving viral diseases facing the human population. The Board of Directors of the Global Virus Network (GVN) has elected Dr. Vermund to serve as President upon the close of the annual GVN scientific meeting being held October 19-21, 2023, in Monaco.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231012987020/en/
Sten Vermund, MD, PhD, Chairperson of Tevogen Bio's Innovation and Public Health Advisory Board (Photo: Business Wire)
Through Dr. Vermund’s extensive background in infectious disease epidemiology and pediatrics, and his significant leadership experience, he is uniquely positioned to contribute to the global effort against viral diseases. His new role at the Global Virus Network will further enable him to facilitate international collaboration among the virology community, fostering a proactive approach towards the prevention, control, and treatment of viral outbreaks globally. Dr. Vermund continues faculty work at the Yale School of Public Health, where he served as Dean from 2017-2022.
Tevogen Bio is immensely proud of Dr. Vermund's appointment, recognizing it as a testament to his exceptional expertise, dedication, and the influential impact he has in the field of public health and virology. This new appointment complements his ongoing contributions at Tevogen Bio, where he continues to provide invaluable guidance on innovation and public health initiatives.
"Dr. Vermund's appointment is a significant acknowledgment of his outstanding contributions to the global health community," said Ryan Saadi, MD, MPH, CEO of Tevogen Bio. "His comprehensive expertise and distinguished leadership continue to be a catalyst for advancements in virology and public health both within our organization and the broader scientific community. We look forward to supporting both Dr. Vermund and the GVN in their endeavors and are excited about the positive impact his presidency will have on global viral and pandemic threat preparedness and response.”
About Tevogen Bio
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
Forward Looking Statements
This press release contains certain forward-looking statements relating to the Tevogen Bio and its business, including without limitation statements regarding the benefits of Mr. Vermund’s appointment as President of the Global Virus Network and the product candidates, products, markets, and expected future performance and market opportunities of Tevogen Bio. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under Tevogen Bio’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “believe,” “potential,” and “possible,” or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which Tevogen Bio expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between Tevogen Bio’s expectations and actual results, including, among others: changes in the markets in which Tevogen Bio competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen Bio may not be able to execute its growth strategies; Tevogen Bio’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review and approval and commercial development; risks associated with intellectual property protection; and other risks related to matters that could affect Tevogen Bio’s future financial results, including the commercial potential, sales, and pricing of Tevogen Bio’s products. Except as required by law, Tevogen Bio undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.
View source version on businesswire.com:https://www.businesswire.com/news/home/20231012987020/en/
CONTACT: Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Tevogen Bio
Copyright Business Wire 2023.
PUB: 10/12/2023 04:35 PM/DISC: 10/12/2023 04:35 PM
http://www.businesswire.com/news/home/20231012987020/en
